BCLI
Income statement / Annual
Last year (2023), Brainstorm Cell Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Brainstorm Cell Therapeutics Inc.'s net income was -$17.19 M.
See Brainstorm Cell Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$366,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$265,000.00
|
$285,000.00
|
$260,000.00
|
$219,000.00
|
$366,000.00
|
$110,000.00
|
$85,000.00
|
$77,000.00
|
$87,000.00
|
$0.00
|
| Gross Profit |
-$265,000.00
|
-$285,000.00
|
-$260,000.00
|
-$219,000.00
|
-$732,000.00
|
-$110,000.00
|
-$85,000.00
|
-$77,000.00
|
-$87,000.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$10.48 M
|
$13.96 M
|
$15.24 M
|
$22.33 M
|
$17.20 M
|
$8.29 M
|
$977,000.00
|
$2.25 M
|
$4.95 M
|
$4.77 M
|
| General & Administrative Expenses |
$10.69 M
|
$10.87 M
|
$9.30 M
|
$9.36 M
|
$5.80 M
|
$5.77 M
|
$4.02 M
|
$2.83 M
|
$3.59 M
|
$2.65 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.69 M
|
$10.87 M
|
$9.30 M
|
$9.36 M
|
$5.80 M
|
$5.77 M
|
$4.02 M
|
$2.83 M
|
$3.59 M
|
$2.65 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$21.17 M
|
$24.82 M
|
$24.54 M
|
$31.68 M
|
$23.00 M
|
$14.06 M
|
$5.00 M
|
$5.08 M
|
$8.54 M
|
$7.42 M
|
| Cost And Expenses |
$21.44 M
|
$24.82 M
|
$24.54 M
|
$31.68 M
|
$23.00 M
|
$14.06 M
|
$5.00 M
|
$5.08 M
|
$8.54 M
|
$7.42 M
|
| Interest Income |
$0.00
|
$545,000.00
|
$82,000.00
|
$127.00
|
$252.00
|
$0.00
|
$47,000.00
|
$101,000.00
|
$48,000.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$265,000.00
|
$285,000.00
|
$260,000.00
|
$219,000.00
|
$164,000.00
|
$110,000.00
|
$85,000.00
|
$77,000.00
|
$87,000.00
|
$1.83 M
|
| EBITDA |
-$16.93 M |
-$23.99 M |
-$24.28 M |
-$31.47 M |
-$23.09 M |
-$13.84 M |
-$4.87 M |
-$4.91 M |
-$8.40 M |
-$7.32 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
62.4
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
62.84
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$4.25 M
|
$545,000.00
|
$82,000.00
|
-$127,000.00
|
-$252,000.00
|
$115,000.00
|
$47,000.00
|
$101,000.00
|
$48,000.00
|
-$1.83 M
|
| Income Before Tax |
-$17.19 M
|
-$24.28 M
|
-$24.46 M
|
-$31.81 M
|
-$23.25 M
|
-$13.95 M
|
-$4.95 M
|
-$4.98 M
|
-$8.49 M
|
-$9.25 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
63.53
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$545,000.00
|
-$82,000.00
|
$127,000.00
|
$252,000.00
|
-$115,000.00
|
-$47,000.00
|
-$101,000.00
|
-$48,000.00
|
-$1.83 M
|
| Net Income |
-$17.19 M
|
-$23.73 M
|
-$24.38 M
|
-$31.94 M
|
-$23.51 M
|
-$13.83 M
|
-$4.95 M
|
-$4.98 M
|
-$8.49 M
|
-$9.25 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
64.22
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.4 |
-0.65 |
-0.67 |
-1.07 |
-1.07 |
-0.69 |
-0.26 |
-0.27 |
-0.46 |
-0.68 |
| EPS Diluted |
-0.4 |
-0.65 |
-0.67 |
-1.07 |
-1.07 |
-0.69 |
-0.26 |
-0.27 |
-0.46 |
-0.68 |
| Weighted Average Shares Out |
$42.98 M
|
$36.51 M
|
$36.18 M
|
$29.85 M
|
$21.91 M
|
$20.00 M
|
$18.78 M
|
$18.66 M
|
$18.41 M
|
$13.66 M
|
| Weighted Average Shares Out Diluted |
$43.08 M
|
$36.51 M
|
$36.18 M
|
$29.85 M
|
$21.91 M
|
$20.00 M
|
$18.78 M
|
$18.66 M
|
$18.41 M
|
$13.66 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
